SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-23-093897
Filing Date
2023-12-07
Accepted
2023-12-07 08:50:05
Documents
50
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0923_virpaxpharma.htm   iXBRL 10-Q 610213
2 CERTIFICATION f10q0923ex31-1_virpax.htm EX-31.1 10169
3 CERTIFICATION f10q0923ex31-2_virpax.htm EX-31.2 10179
4 CERTIFICATION f10q0923ex32-1_virpax.htm EX-32.1 8837
  Complete submission text file 0001213900-23-093897.txt   3291255

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE vrpx-20230930.xsd EX-101.SCH 35537
6 XBRL CALCULATION FILE vrpx-20230930_cal.xml EX-101.CAL 15227
7 XBRL DEFINITION FILE vrpx-20230930_def.xml EX-101.DEF 155911
8 XBRL LABEL FILE vrpx-20230930_lab.xml EX-101.LAB 315333
9 XBRL PRESENTATION FILE vrpx-20230930_pre.xml EX-101.PRE 166606
44 EXTRACTED XBRL INSTANCE DOCUMENT f10q0923_virpaxpharma_htm.xml XML 310344
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-4597
Virpax Pharmaceuticals, Inc. (Filer) CIK: 0001708331 (see all company filings)

IRS No.: 821510982 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40064 | Film No.: 231471168
SIC: 2834 Pharmaceutical Preparations